Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3865234 | The Journal of Urology | 2013 | 6 Pages |
Abstract
Treatment with tadalafil once daily for lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia showed no negative impact on bladder function as measured by detrusor pressure at maximum urinary flow rate or on any other urodynamic parameter assessed. Nonetheless men receiving tadalafil reported significant improvements in International Prostate Symptom Score with an adverse events profile similar to other recent studies of tadalafil for lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia.
Keywords
PSAvoided volumeQavePdetQmaxBOOII-PSSPressure flow studiesQmaxBladder outlet obstruction indexPDE5UDSPFsProstate specific antigenErectile dysfunctionurinary bladder neck obstructionUrodynamicsmaximum urinary flow ratePVRLower urinary tract symptomsphosphodiesterase type 5Urodynamic studiesPhosphodiesterase inhibitorsLUTSInternational Prostate Symptom ScoreBenign prostatic hyperplasiaBPHProstatic hyperplasiapost-void residual
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Roger Dmochowski, Claus Roehrborn, Suzanne Klise, Lei Xu, Jed Kaminetsky, Stephen Kraus,